320 related articles for article (PubMed ID: 23192697)
1. Increased 3-hydroxykynurenine serum concentrations differentiate Alzheimer's disease patients from controls.
Schwarz MJ; Guillemin GJ; Teipel SJ; Buerger K; Hampel H
Eur Arch Psychiatry Clin Neurosci; 2013 Jun; 263(4):345-52. PubMed ID: 23192697
[TBL] [Abstract][Full Text] [Related]
2. Kynurenine and its metabolites in Alzheimer's disease patients.
Gulaj E; Pawlak K; Bien B; Pawlak D
Adv Med Sci; 2010; 55(2):204-11. PubMed ID: 20639188
[TBL] [Abstract][Full Text] [Related]
3. Involvement of the kynurenine pathway in human glioma pathophysiology.
Adams S; Teo C; McDonald KL; Zinger A; Bustamante S; Lim CK; Sundaram G; Braidy N; Brew BJ; Guillemin GJ
PLoS One; 2014; 9(11):e112945. PubMed ID: 25415278
[TBL] [Abstract][Full Text] [Related]
4. Dynamic changes in kynurenine pathway metabolites in multiple sclerosis: A systematic review.
Fathi M; Vakili K; Yaghoobpoor S; Tavasol A; Jazi K; Mohamadkhani A; Klegeris A; McElhinney A; Mafi Z; Hajiesmaeili M; Sayehmiri F
Front Immunol; 2022; 13():1013784. PubMed ID: 36426364
[TBL] [Abstract][Full Text] [Related]
5. Activation of the kynurenine pathway and increased production of the excitotoxin quinolinic acid following traumatic brain injury in humans.
Yan EB; Frugier T; Lim CK; Heng B; Sundaram G; Tan M; Rosenfeld JV; Walker DW; Guillemin GJ; Morganti-Kossmann MC
J Neuroinflammation; 2015 May; 12():110. PubMed ID: 26025142
[TBL] [Abstract][Full Text] [Related]
6. Increased breakdown of kynurenine towards its neurotoxic branch in bipolar disorder.
Birner A; Platzer M; Bengesser SA; Dalkner N; Fellendorf FT; Queissner R; Pilz R; Rauch P; Maget A; Hamm C; Herzog-Eberhard S; Mangge H; Fuchs D; Moll N; Zelzer S; Schütze G; Schwarz M; Reininghaus B; Kapfhammer HP; Reininghaus EZ
PLoS One; 2017; 12(2):e0172699. PubMed ID: 28241062
[TBL] [Abstract][Full Text] [Related]
7. Tryptophan metabolite concentrations in depressed patients before and after electroconvulsive therapy.
Ryan KM; Allers KA; McLoughlin DM; Harkin A
Brain Behav Immun; 2020 Jan; 83():153-162. PubMed ID: 31606477
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of kynurenine pathway metabolism in Toxoplasma gondii-infected mice: implications for schizophrenia.
Notarangelo FM; Wilson EH; Horning KJ; Thomas MA; Harris TH; Fang Q; Hunter CA; Schwarcz R
Schizophr Res; 2014 Jan; 152(1):261-7. PubMed ID: 24345671
[TBL] [Abstract][Full Text] [Related]
9. Kynurenic acid and 3-hydroxykynurenine production from D-kynurenine in mice.
Wang XD; Notarangelo FM; Wang JZ; Schwarcz R
Brain Res; 2012 May; 1455():1-9. PubMed ID: 22498176
[TBL] [Abstract][Full Text] [Related]
10. Dynamic changes in metabolites of the kynurenine pathway in Alzheimer's disease, Parkinson's disease, and Huntington's disease: A systematic Review and meta-analysis.
Fathi M; Vakili K; Yaghoobpoor S; Tavasol A; Jazi K; Hajibeygi R; Shool S; Sodeifian F; Klegeris A; McElhinney A; Tavirani MR; Sayehmiri F
Front Immunol; 2022; 13():997240. PubMed ID: 36263032
[TBL] [Abstract][Full Text] [Related]
11. Kynurenine pathway metabolites in cerebrospinal fluid and serum in complex partial seizures.
Heyes MP; Saito K; Devinsky O; Nadi NS
Epilepsia; 1994; 35(2):251-7. PubMed ID: 8156942
[TBL] [Abstract][Full Text] [Related]
12. A validated UHPLC-MS method for tryptophan metabolites: Application in the diagnosis of multiple sclerosis.
Tömösi F; Kecskeméti G; Cseh EK; Szabó E; Rajda C; Kormány R; Szabó Z; Vécsei L; Janáky T
J Pharm Biomed Anal; 2020 Jun; 185():113246. PubMed ID: 32182446
[TBL] [Abstract][Full Text] [Related]
13. Kynurenine 3-Monooxygenase Activity in Human Primary Neurons and Effect on Cellular Bioenergetics Identifies New Neurotoxic Mechanisms.
Castellano-Gonzalez G; Jacobs KR; Don E; Cole NJ; Adams S; Lim CK; Lovejoy DB; Guillemin GJ
Neurotox Res; 2019 Apr; 35(3):530-541. PubMed ID: 30666558
[TBL] [Abstract][Full Text] [Related]
14. Relationship between neurotoxic kynurenine metabolites and reductions in right medial prefrontal cortical thickness in major depressive disorder.
Meier TB; Drevets WC; Wurfel BE; Ford BN; Morris HM; Victor TA; Bodurka J; Teague TK; Dantzer R; Savitz J
Brain Behav Immun; 2016 Mar; 53():39-48. PubMed ID: 26546831
[TBL] [Abstract][Full Text] [Related]
15. The kynurenine pathway in neurodegenerative diseases: mechanistic and therapeutic considerations.
Tan L; Yu JT; Tan L
J Neurol Sci; 2012 Dec; 323(1-2):1-8. PubMed ID: 22939820
[TBL] [Abstract][Full Text] [Related]
16. Altered serum levels of kynurenine metabolites in patients affected by cluster headache.
Curto M; Lionetto L; Negro A; Capi M; Perugino F; Fazio F; Giamberardino MA; Simmaco M; Nicoletti F; Martelletti P
J Headache Pain; 2015; 17(1):27. PubMed ID: 27000870
[TBL] [Abstract][Full Text] [Related]
17. The kynurenine pathway and inflammation in amyotrophic lateral sclerosis.
Chen Y; Stankovic R; Cullen KM; Meininger V; Garner B; Coggan S; Grant R; Brew BJ; Guillemin GJ
Neurotox Res; 2010 Aug; 18(2):132-42. PubMed ID: 19921535
[TBL] [Abstract][Full Text] [Related]
18. Tryptophan, kynurenine, and kynurenine metabolites: Relationship to lifetime aggression and inflammatory markers in human subjects.
Coccaro EF; Lee R; Fanning JR; Fuchs D; Goiny M; Erhardt S; Christensen K; Brundin L; Coussons-Read M
Psychoneuroendocrinology; 2016 Sep; 71():189-96. PubMed ID: 27318828
[TBL] [Abstract][Full Text] [Related]
19. Peripheral and central kynurenine pathway abnormalities in major depression.
Paul ER; Schwieler L; Erhardt S; Boda S; Trepci A; Kämpe R; Asratian A; Holm L; Yngve A; Dantzer R; Heilig M; Hamilton JP; Samuelsson M
Brain Behav Immun; 2022 Mar; 101():136-145. PubMed ID: 34999196
[TBL] [Abstract][Full Text] [Related]
20. Kynurenine metabolism in Alzheimer's disease.
Baran H; Jellinger K; Deecke L
J Neural Transm (Vienna); 1999; 106(2):165-81. PubMed ID: 10226937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
